GleamWall
中文EN

BCDA BioCardia, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 925741 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-3.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-950.1%
ROA-230.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets73.8%
Debt / equity0.00x
Current ratio1.12x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-22.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$0$0
R&D expense$1.24M$893,000$1.24M$1.13M$936,000$1.37M$1.53M$1.42M
SG&A expense$600,000$730,000$1.03M$885,000$552,000$683,000$1.20M$906,000
Operating income-$1.83M-$1.62M-$2.27M-$2.01M-$1.49M-$2.05M-$2.73M-$2.32M
Income tax$0$0$0$0$0$0$0$0
Net income-$1.82M-$1.61M-$2.26M-$1.98M-$1.48M-$2.05M-$2.71M-$2.30M
EBITDA-$1.83M-$1.62M-$2.26M-$2.01M-$1.48M-$2.05M-$2.71M-$2.31M
EPS (basic)-0.12-0.13-0.21—-0.24-0.40-0.59—
EPS (diluted)——-0.21—-0.24-0.40-0.59—
Weighted avg. shares (diluted)——10.81M—6.28M5.06M4.64M—
Balance sheet
Cash & equivalents$2.22M$4.12M$951,000$2.50M$5.29M$980,000$949,000$2.37M
Receivables$30,000$30,000$20,000$20,000—$10,000—$0
Current assets$2.33M$4.30M$1.14M$2.73M$5.37M$1.20M$1.17M$2.62M
PP&E, net$12,000$13,000$16,000$16,000$13,000$17,000$16,000$33,000
Total assets$3.07M$4.75M$1.71M$3.41M$6.15M$2.09M$2.17M$3.72M
Current liabilities$2.09M$2.06M$2.78M$2.43M$3.31M$3.64M$3.23M$2.32M
Total liabilities$2.24M$2.06M$2.78M$2.52M$3.52M$3.98M$3.69M$2.89M
Shareholders' equity$835,000$2.70M-$1.07M$895,000$2.63M-$1.89M-$1.52M$837,000
Shares outstanding15.14M14.98M10.94M10.76M10.61M5.50M4.68M4.60M
Cash flow statement
Operating cash flow-$1.72M-$1.74M-$1.66M-$2.50M-$1.67M-$1.65M-$1.62M-$2.57M
Capital expenditure$1,000$0$3,000$6,000$0$1,000$0$1,000
Free cash flow-$1.72M-$1.74M-$1.66M-$2.50M-$1.67M-$1.65M-$1.62M-$2.57M
Investing cash flow-$1,000$0-$3,000-$6,000$0-$1,000$0-$1,000
Financing cash flow-$172,000$4.90M$117,000-$288,000$5.98M$1.68M$196,000$15,000
Depreciation & amortization$2,000$3,000$3,000$3,000$4,000$5,000$12,000$15,000
Stock-based compensation$117,000$109,000$113,000$85,000$77,000$98,000$170,000$176,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.